Data gathered: May 17
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $133.04 |
| Target Price | Sign up |
| Volume | 2,890,000 |
| Market Cap | $592B |
| Year Range | $87.15 - $134.95 |
| Dividend Yield | 1.03% |
| PE Ratio | 46.31 |
| Revenue per Employee | $4,570,627 |
| Industry | Drug Manufacturers |
In the news
 |
Dimensional Fund Advisors LP Reduces Stake in Novo Nordisk A/S (NYSE:NVO)May 16 - ETF Daily News |
Denmark Raises Growth Forecast as Novo Nordisk Expands OutputMay 16 - Yahoo Entertainment |
|
 |
Ozempic maker Novo Nordisk says it will study drug’s effects on alcohol consumption but isn’t focused on addiction | CNNMay 15 - CNN |
 |
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk ConfirmsMay 15 - Biztoc.com |
 |
Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 DrugsMay 15 - Forbes |
 |
Novo Nordisk Executive Reports Share SaleMay 15 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 28.5B | 0.700 |
| Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 32.8B | 5.000 |
| Q2 '23 | 54.3B | 7.86B | 46.4B | 19.4B | 26.7B | 17.410 |
| Q1 '23 | 53.4B | 8.18B | 45.2B | 19.8B | 27.6B | 8.780 |
| Q4 '22 | 48.1B | 8.26B | 39.8B | 13.6B | 10.3B | 6.020 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$154.28 0% | 60 |
 |
Eli Lilly and CompanyLLY |
$771.12 0% | 71 |
 |
PfizerPFE |
$28.92 0% | 39 |
 |
AstrazenecaAZN |
$77.04 0% | 58 |
 |
AbbVieABBV |
$164.33 0% | 58 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Mar 6, 24 | Sell | $50K - $100K |
| Thomas Tuberville Republican |
Feb 14, 24 | Sell | $15K - $50K |
| Rohit Khanna Democrat |
Oct 6, 23 | Buy | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $592B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 46.31.
How Many People Work at Novo Nordisk?
As of our latest update, Novo Nordisk employed approximately 50,816 people worldwide. However, it's important to note that Novo Nordisk's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Novo Nordisk's revenue per employee?
$4,570,627. To calculate Novo Nordisk's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $133.04.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.03%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.